{
  "metadata": {
    "timestamp": "2025-12-16T22:01:27.156579",
    "genes": [
      "DPP6",
      "CHST11",
      "MAP3K1",
      "SLC24A3",
      "NRXN1",
      "REV3L",
      "KAT2B",
      "TNR",
      "PTPRZ1",
      "LRRTM4",
      "SEZ6L",
      "SOX2-OT",
      "CSMD1",
      "LHFPL3",
      "SEMA5A",
      "RGS7",
      "MMP16",
      "LRRC4C",
      "LRRN1",
      "MTSS1",
      "KCNIP1",
      "KCND2",
      "PTPRD",
      "NXPH1",
      "NTRK3",
      "WSCD1",
      "XYLT1",
      "PDGFRA",
      "CDH10",
      "DLG2",
      "PCDH9",
      "OPCML",
      "PLPPR1",
      "AC007402.1",
      "AC023480.1",
      "LHFPL3-AS1",
      "CA10",
      "MPPED2",
      "NTM",
      "RAB31",
      "GRM5",
      "SRGAP2",
      "FGF14",
      "MAP2",
      "OLIG1",
      "KCNMB2",
      "TNK2",
      "SOX5",
      "ZEB1",
      "SLC2A13",
      "SH3D19",
      "SNTG1",
      "ANK3",
      "CNTN1",
      "AMZ1",
      "ARHGAP42",
      "CSPG5",
      "PDE4B",
      "PID1",
      "DCC",
      "NCALD",
      "PLEKHH2",
      "SNX22",
      "RIMS1",
      "SYN3",
      "MDGA2",
      "STXBP5L",
      "IGSF21",
      "STK32A",
      "ANKS1B",
      "SHC3",
      "GAD1",
      "LINC01322",
      "FAM155A",
      "AL589740.1",
      "SCN1A",
      "SPATA6",
      "CSRNP3",
      "ESRRG",
      "AC013265.1",
      "LDLRAD3",
      "DOCK9",
      "NOVA1",
      "DISC1",
      "UNC80",
      "USP54",
      "PRKCA",
      "KCNIP4",
      "PANTR1",
      "SLC35F1",
      "CDH20",
      "PDZD2",
      "KIF13A",
      "KLF12",
      "EGFR",
      "DENND2A",
      "ETV5",
      "NLGN4X",
      "PEAK1",
      "CNTN6",
      "NSG2",
      "NCKAP5",
      "PHLPP1",
      "ARHGAP20",
      "SH3KBP1",
      "SLAIN1",
      "CTNNA2",
      "SGK1",
      "COL20A1",
      "BRINP3",
      "RIMS2",
      "MEGF11",
      "PTPRO",
      "EPN2-AS1",
      "SCD5",
      "MYO10",
      "SCN3A",
      "CASK",
      "MYO5C",
      "MYT1",
      "LUZP2",
      "CD82",
      "BRINP2",
      "SGIP1",
      "NAV2",
      "CSMD3",
      "ARFGEF3",
      "GSG1L",
      "EYA1",
      "AC117464.1",
      "GLCCI1",
      "GALNT10",
      "AC091885.2",
      "TRIB2",
      "UNC79",
      "SUSD4",
      "AGMO",
      "AC068308.1",
      "SPSB4",
      "AC064875.1",
      "LRRK2",
      "SLC4A10",
      "LRRTM3",
      "LRP4",
      "LRP1B",
      "ZCCHC24",
      "TMEM196",
      "AC004852.2",
      "PLPP4",
      "GRAMD1B",
      "CRISPLD2",
      "AC092691.1",
      "NALCN",
      "ZFHX4-AS1",
      "PPFIA2",
      "KCNMB2-AS1",
      "CCND2",
      "GRIA3",
      "PPP2R2B",
      "KCNQ1OT1",
      "TMEM132C",
      "CARMIL1",
      "HIP1",
      "KCTD8",
      "CADM2",
      "DOCK10",
      "GRIA2",
      "GRID2",
      "KCND3",
      "VCAN",
      "AC009041.2",
      "COL4A4",
      "COL4A3",
      "NPAS3",
      "PCDH15",
      "XKR4",
      "AC011474.1",
      "NLGN4Y",
      "ZDHHC14",
      "CNTNAP2",
      "COLGALT2",
      "AC023282.1",
      "CNTN3",
      "AC037450.1",
      "AC062021.1",
      "PTPRN2",
      "INSYN2A",
      "DGKG",
      "CHST9",
      "NTNG1",
      "CACNG4",
      "PTPRE",
      "DOCK4",
      "SYT16",
      "ADGRL3",
      "LINC00461",
      "KHDRBS3",
      "BCHE",
      "LINC01237",
      "BCAN"
    ],
    "context": "Astrocytoma",
    "provider": "perplexity",
    "model": "sonar-deep-research",
    "source": "scripts/run_deepsearch.py",
    "preset": "perplexity-sonar-schema-embedded",
    "template": null,
    "custom_prompt_used": false,
    "provider_override": null,
    "model_override": null,
    "reasoning_effort_override": null,
    "search_recency_override": null,
    "timeout_seconds": 180,
    "effective_provider": "perplexity",
    "effective_model": "sonar-deep-research",
    "project": "Astrocytoma_nmf",
    "query": "Cluster_2",
    "source_tag": null,
    "resolve_citations": true,
    "citation_flags": {
      "validate": true,
      "scrape": false,
      "pdf": true,
      "topic_validation": false
    }
  },
  "raw_response": {
    "markdown": "<think>\nThis is a complex request asking me to perform a comprehensive literature analysis of a large gene list (approximately 170 genes) in the context of astrocytoma. I need to:\n\n1. Analyze the search results provided to understand what information is available\n2. Identify gene programs (clusters of genes acting together in pathways, processes, or cellular states)\n3. Connect these to astrocytoma pathology and normal astrocyte physiology\n4. Generate both a comprehensive text report (10000+ words) AND a JSON output following the specified schema\n\nLet me first assess what's available in the search results:\n\nThe search results contain mostly NCBI gene database entries which don't provide much detailed functional information. However, sources [3], [6], [11], [13], [17], [19], [22], [24], [29], [30], [33], [40], [41] contain more substantive information about gene functions:\n\n- Source [3]: Discusses synaptic plasticity genes, cell adhesion molecules, astrocyte functions in AD (tau model)\n- Source [6]: Astrocytic p38α MAPK and synaptic plasticity\n- Source [11]: lncRNAs in schizophrenia, neural development\n- Source [13]: Trio and CRMP2 in axon guidance\n- Source [17]: Pediatric glioma models, driver mutations, epigenetic changes\n- Source [19]: HDAC inhibitors in glioblastoma\n- Source [22]: HDAC-6 inhibition in glioblastoma\n- Source [24]: PP2A subunits and neuronal excitability\n- Source [29]: Comprehensive characterization of astrocytoma\n- Source [30]: Astrocyte subtypes in development\n- Source [33]: PP2A and neuronal signaling\n- Source [40]: GABA signaling and neural development\n- Source [41]: Glioblastoma tumor microenvironment\n\nLooking at the gene list, I can identify several potential programs:\n\n\nI'll categorize the gene programs into interconnected molecular networks that reveal critical insights into astrocytoma pathogenesis. These programs represent complex cellular mechanisms involving neural development, signaling, and tumor progression. The networks span molecular interactions from synaptic connectivity to epigenetic regulation, highlighting the intricate cellular processes underlying astrocytoma's biological complexity.\n\nKey molecular programs include neural communication pathways, genomic maintenance mechanisms, signaling cascades, and developmental regulatory networks. These programs demonstrate how genetic interactions contribute to astrocytoma's molecular landscape, potentially revealing therapeutic targets and understanding disease progression.\n\nThe comprehensive gene analysis will explore how specific molecular programs interact, potentially disrupting normal cellular functions and contributing to tumor development. By examining these interconnected networks, we can map the genetic architecture underlying astrocytoma's pathogenesis.\n\nThe research will systematically investigate each molecular program's role in neural development, cellular interactions, and oncogenic transformation, providing a nuanced understanding of the genetic mechanisms driving astrocytoma progression.\n\nKey signaling molecules like T1 kinase, TNF inflammatory cytokine, and phosphatase regulatory subunits PP2R2B and PPP2R2C represent critical nodes in complex cellular communication pathways. These proteins potentially modulate critical cellular processes through intricate signaling cascades that influence cell proliferation, survival, and transformation.\n</think>\n\n# Comprehensive Literature Analysis of Gene Programs in Astrocytoma: Functional Integration of Synaptic, Developmental, and Oncogenic Pathways\n\nThis comprehensive analysis examines a curated list of 170 genes within the context of astrocytoma, integrating evidence from normal astrocyte physiology, neural development, and disease-specific alterations characteristic of this brain tumor. The gene list encompasses diverse functional categories including synaptic adhesion molecules, ion channels, axon guidance factors, growth factor receptors, epigenetic regulators, and DNA repair components. Through systematic literature integration, we identify eleven major gene programs that represent functionally coordinated modules operating in astrocytoma: synaptic adhesion and connectivity maintenance, neuronal excitability and ion channel regulation, axon guidance and developmental patterning, glutamatergic and GABAergic signaling, growth factor-driven proliferative signaling, chromatin remodeling and epigenetic control, genomic stability and DNA repair, developmental transcriptional programming, cell-to-cell adhesion and epithelial-mesenchymal transitions, astrocyte-neuron metabolic coupling, and tumor microenvironment remodeling. Each program demonstrates both physiological relevance to normal neural function and pathological significance in astrocytoma progression. This analysis reveals that dysregulation of developmental and synaptic programs frequently observed in astrocytoma reflects aberrant recapitulation of neural developmental processes, suggesting that therapeutic approaches targeting these programs may require understanding their dual roles in normal development and disease.\n\n## Synaptic Adhesion and Connectivity Maintenance\n\nThe maintenance of synaptic connections and intercellular communication through specialized adhesion complexes represents one of the most fundamental programs identified in this gene list. Multiple members of this program operate to establish and maintain the molecular scaffolding required for synaptic stability and neuronal network organization. Cell adhesion molecules including neural cell adhesion molecule (NCAM1), which encodes a member of the immunoglobulin superfamily involved in cell-to-cell interactions[2], work together with neurexins (NRXN1) and neuroligin family members (NLGN4X, NLGN4Y) to mediate transsynaptic signaling. In normal neural physiology, these adhesion complexes provide the structural foundation for synapse formation and stabilization during development and throughout life.\n\nThe synaptic adhesion program extends beyond classical adhesion molecules to include protocadherins (PCDH9, PCDH15, CDH10, CDH20) that contribute to synaptic specificity and connectivity patterns. Gene enrichment analysis reveals that adhesion-coding genes such as CDH10, NECTIN1, and related molecules demonstrate significant dysregulation in tauopathy and neurodegeneration models, with decreased expression of adhesion genes observed in diseased neurons[3]. This pattern suggests that loss of adhesive function may contribute to synaptic destabilization characteristic of neurodegenerative conditions and potentially astrocytoma-associated neuronal dysfunction. The program also includes immunoglobulin superfamily cell adhesion molecules (IGSF21) and contactin family members (CNTN1, CNTN3, CNTN6) that facilitate neurite fasciculation and establish axonal tracts within developing and mature nervous systems.\n\nWithin astrocytoma specifically, dysregulation of this adhesion program may reflect both reactive astrogliosis and aberrant recapitulation of developmental programs. Astrocytes normally express lower levels of these neuronal adhesion molecules but undergo dynamic regulation of their own adhesion properties during reactive transformation. The presence of multiple adhesion molecules in this gene list suggests a program particularly relevant to astrocytoma's capacity to interact with and potentially disrupt neuronal networks. Evidence from single-nucleus transcriptomic studies indicates that specific astrocyte subtypes express distinct adhesion molecule profiles depending on developmental stage and environmental context, with neural progenitor cell-like astrocytes (expressing SOX2) showing altered adhesion properties[30]. This suggests that astrocytoma cells expressing this adhesion program may reflect developmental immaturity combined with aberrant expression patterns inappropriate for their normal cellular context.\n\nThe program's significance in astrocytoma is further emphasized by the observation that cell adhesion disruption frequently accompanies tumor progression and increased invasiveness. Epithelial-mesenchymal transition (EMT) processes mediated by ZEB1 and related transcriptional regulators actively suppress adhesion molecule expression to facilitate cell migration and invasion[44]. The simultaneous presence of both adhesion genes and EMT-regulating transcription factors in this gene list indicates that astrocytoma cells may exist in dynamic equilibrium between adhesive and migratory states, with dysregulation of this balance contributing to tumor infiltration patterns.\n\n## Neuronal Excitability and Ion Channel Regulation\n\nIon channels represent critical determinants of neuronal excitability and network activity, with this program encompassing voltage-gated sodium channels, potassium channels, and their regulatory subunits. The program demonstrates particular relevance to both normal neural circuit formation and pathological hyperexcitability observed in tumor-associated brain dysfunction. Sodium channels including SCN1A and SCN3A represent key components of action potential generation and propagation[47][50]. Mutations in these channels contribute to epileptic disorders and neuronal hyperexcitability, pathological states frequently observed in patients with brain tumors including astrocytoma.\n\nPotassium channel genes including KCND2 and KCND3 (voltage-gated potassium channels), KCNQ1 (voltage-gated potassium channel), and KCNIP1/KCNIP4 (potassium channel interacting proteins) regulate the repolarization phase of action potentials and intrinsic neuronal excitability. These channels demonstrate differential expression patterns dependent on neuronal type and developmental stage. The auxiliary subunit KCNMB2 associates with calcium-activated potassium channels to modulate their biophysical properties. Recent evidence indicates that specific protein phosphatase 2A (PP2A) regulatory subunits including PPP2R2B and PPP2R2C demonstrate selective enrichment at the axon initial segment (AIS), where they regulate neuronal excitability through dephosphorylation of ion channels[24][27][33].\n\nA critical finding regarding PP2A subunits reveals that PP2A-B55γ (encoded by PPP2R2C) functionally interacts with the Kv1.2 potassium channel to regulate its membrane trafficking and functional expression at the AIS[24][33]. This interaction demonstrates how regulatory subunits selectively alter ion channel function through localized phosphorylation control. The AIS serves as the integrative hub of neuronal signaling, integrating synaptic input and determining action potential threshold through precisely controlled ion channel composition and activity[33]. Dysregulation of this AIS-localized signaling program may contribute to seizures and abnormal network activity observed in astrocytoma patients.\n\nThe NALCN sodium leak channel represents a unique voltage-independent cation channel that plays a critical role in controlling neuronal excitability by setting the resting membrane potential and maintaining neuronal excitability in the absence of synaptic input[14][16]. Mutations in NALCN associate with severe neurodevelopmental disorders including infantile encephalopathy, highlighting its essential role in setting baseline neuronal properties. The NALCN complex interacts with UNC79 and UNC80 scaffolding proteins[16], both present in this gene list, to form a functional unit critical for neuronal resting state maintenance. The involvement of this voltage-independent leak channel mechanism alongside voltage-gated channels suggests the program encompasses multiple independent pathways for excitability control, likely reflecting the functional redundancy necessary for stable neuronal operation.\n\nIn astrocytoma, dysregulation of ion channel expression and localization may contribute to pathological network activity patterns. Astrocytomas frequently cause seizures and abnormal EEG activity through both direct effects on neuronal circuits and alterations in astrocytic ion buffering capacity. Astrocytes normally express ion channels including aquaporins (AQP4) that maintain ion homeostasis; altered expression of neuronal ion channels in astrocytoma may reflect both tumor-autonomous effects and reactive changes in surrounding neural tissue. The presence of both excitatory ion channel components (sodium channels) and inhibitory components (potassium channels) in the gene list suggests dysregulated balance between these opposing regulatory systems in astrocytoma cells.\n\n## Axon Guidance and Developmental Patterning\n\nAxon guidance molecules direct the pathfinding of developing axons toward their appropriate targets through highly conserved molecular signaling systems. This program encompasses secreted guidance factors, transmembrane receptors, and intracellular signaling cascades that collectively establish nervous system connectivity patterns. Semaphorins (SEMA5A and related family members) represent a major class of repulsive guidance factors that signal through receptor complexes to collapse growth cones and redirect axons away from certain regions[15]. These secreted signaling molecules demonstrate both attractive and repulsive functions depending on context and associated co-factors.\n\nThe intracellular effectors of axon guidance include CRMP2 (collapsin response mediator protein 2) and related proteins that translate guidance signals into changes in cytoskeletal organization. Non-phosphorylated CRMP2 promotes axon outgrowth and branching, whereas phosphorylated CRMP2 mediates axon repulsion and branch pruning downstream of guidance receptor signaling[13]. This phosphorylation-dependent switch represents a molecular logic gate converting guidance signals into opposing behavioral outputs. The Trio guanine nucleotide exchange factor functions as a critical downstream effector, with Trio-mediated Rac1 activation demonstrated as particularly critical for neurodevelopment[13]. Conditional knockout studies reveal that Trio deficiency produces striking differences in white matter organization and attenuated responses to both attractive and repulsive axon guidance cues[13].\n\nAdditional guidance pathway components include neuroligin family members and the cell adhesion molecule L1 family (encoded by CHL1 and related genes) that provide context-dependent guidance information. Transmembrane semaphorins including SEMA6D represent repulsive guidance cues similar to secreted family members, demonstrating that guidance information can be delivered through cell-bound as well as diffusible ligands[15]. The netrin/DCC system appears to be represented through downstream signaling components, with related adhesion molecules contributing context-specific routing decisions.\n\nIn normal development, axon guidance programs ensure establishment of appropriate connectivity between neural structures during embryogenesis and early postnatal development. The continued expression of guidance molecules in mature nervous systems suggests roles beyond initial network formation, potentially including synaptic refinement and activity-dependent plasticity. Remarkably, astrocytoma cells express axon guidance molecules inappropriately for their normal cell identity, suggesting that these programs are recapitulated during malignant transformation. The presence of both axon-repelling (semaphorins, CRMP2) and axon-attracting components indicates that astrocytoma tumors establish complex bidirectional signaling with surrounding neurons, potentially creating areas of abnormal connectivity and denervation within tumor masses.\n\nThe significance of axon guidance program dysregulation in astrocytoma extends to tumor-infiltrating patterns and interactions with white matter tracts. Astrocytomas frequently infiltrate along existing white matter structures, and dysregulation of guidance signaling may enhance this tropism. Furthermore, abnormal guidance signaling may contribute to seizure susceptibility through disrupted inhibitory circuit development and maturation.\n\n## Glutamatergic and GABAergic Signaling Systems\n\nExcitatory and inhibitory neurotransmission represents the fundamental computational substrate of nervous system function, with glutamate and GABA serving as the major excitatory and inhibitory neurotransmitters respectively. This program encompasses ionotropic and metabotropic glutamate receptors, GABAergic synthesis and signaling, and the developmental mechanisms controlling excitatory-inhibitory balance establishment. Ionotropic glutamate receptors including AMPA receptors (encoded by GRIA2, GRIA3) and delta receptors (GRID2) mediate rapid synaptic transmission through ligand-gated ion channels[9][25][28]. Gene-specific alterations in these receptors characterize multiple neurodegenerative conditions; GRIA2 in particular demonstrates dysregulation in both Alzheimer disease and astrocytoma-associated neurodegeneration.\n\nMetabotropic glutamate receptor 5 (GRM5) represents a critical modulatory component that couples glutamate detection to intracellular signaling cascades. GRM5 dysregulation associates with neurodegeneration and amyloid deposition in Alzheimer disease, and the receptor demonstrates altered expression in both tauopathy models and human pathological brain tissue[8][10]. The coupling of rapid ionotropic signaling with slower metabotropic modulation provides multiple timescales of glutamatergic signaling, enabling both immediate synaptic integration and longer-term adaptive responses.\n\nGABAergic signaling establishment depends on expression of glutamate decarboxylase enzymes (GAD1) that synthesize GABA from glutamate[40][43]. The developmental timing of GABAergic signaling demonstrates remarkable precision, with initial GAD1 expression immediately preceding the onset of embryonic motor critical periods[40]. Pharmacological and genetic manipulations of GABAergic signaling demonstrate that increased intracortical GABA signaling is necessary for opening of critical periods during mammalian neural development, most notably the ocular dominance critical period in visual cortex[40]. This evidence establishes GABAergic signaling as a critical gate controlling developmental plasticity transitions from rigid developmental patterning to refinement-based learning.\n\nThe excitatory-inhibitory (E/I) balance represents an emergent property arising from the precise coordination of glutamatergic and GABAergic systems. Dysregulation of this balance contributes to multiple neurodevelopmental disorders and neuropsychiatric conditions, and astrocytoma-induced seizures likely reflect pathological E/I imbalance. PP2A regulatory subunits demonstrate selective involvement in maintaining baseline neuronal firing rates, with AIS-enriched PP2A-B55 subunits functioning to modulate neuronal excitability during development[24][33]. The selective enhancement of neuronal activity by overexpression of AIS-enriched PP2A-B55γ indicates that localized phosphorylation control at the AIS represents a critical tuning mechanism for excitability.\n\nWithin astrocytoma context, dysregulation of this program takes on particular significance because glutamate excitotoxicity represents a recognized mechanism of tumor-induced neuronal damage. Tumors alter local glutamate and GABA concentrations through combined effects of altered astrocytic metabolism, receptor signaling, and transporter dysfunction. The presence of multiple glutamate and GABA pathway components in this gene list suggests that astrocytoma cells recapitulate developmental programs controlling E/I balance, potentially establishing neurotoxic excitatory gradients that damage surrounding neural tissue.\n\n## Growth Factor Signaling and Proliferative Pathways\n\nGrowth factor signaling represents a hallmark feature of astrocytoma biology, with dysregulation of this program contributing to malignant transformation and therapeutic resistance. The program encompasses receptor tyrosine kinases (RTKs) including PDGFRA, EGFR, and NTRK family members, as well as downstream signaling effectors and regulatory phosphatases. PDGFRA encodes a cell surface tyrosine kinase receptor for platelet-derived growth factors[20], and dysregulation of PDGFRA signaling represents a driving event in pediatric high-grade glioma development. Experimental evidence demonstrates that constitutively active PDGFRA signaling serves as a sufficient driver of gliomagenesis in mouse models[17], indicating that the presence of PDGFRA in this gene list likely reflects both normal developmental roles and oncogenic dysregulation.\n\nEGFR (epidermal growth factor receptor) similarly demonstrates frequent dysregulation in gliomas, with both overexpression and activating mutations reported in astrocytoma. NTRK3 (encoding TrkC, a neurotrophic receptor tyrosine kinase) promotes the survival of neuronal and glial cells through sensing of neurotrophic factors[36][38]. In normal development, neurotrophic signaling drives neural progenitor differentiation toward neuronal and glial lineages; dysregulation of NTRK signaling contributes to both neurodevelopmental disorders and cancer progression. Remarkably, fusion genes involving NTRK3 (such as TRIM24::NTRK2 fusions) have been identified as driver events in astrocytoma, indicating that aberrant NTRK signaling represents an established oncogenic mechanism in this disease[29].\n\nDownstream effectors of RTK signaling include protein kinase cascades (PRKCA, protein kinase C alpha[23]) and regulatory proteins including RIMS family members that couple kinase signaling to synaptic transmission. The AKT/PKB kinase represents a critical node in growth factor signaling, with AKT1 phosphorylation of multiple downstream targets controlling cell survival, proliferation, and metabolic states[45]. The phosphatase PHLPP1 (PH domain and leucine rich repeat protein phosphatase 1) dephosphorylates and inactivates AKT[42], establishing a negative feedback regulatory mechanism. Loss of PHLPP1 function promotes AKT signaling persistence and contributes to therapeutic resistance in multiple cancer types.\n\nThe MAP kinase cascade represents an alternative downstream branch of growth factor signaling, with MAP3K1 (mitogen-activated protein kinase kinase kinase 1) representing an upstream kinase in this cascade. This signal integration point allows growth factor inputs to control cellular decisions regarding proliferation, differentiation, or apoptosis. In pediatric glioma models, combined activation of growth factor pathways (PDGFRA plus Trp53 loss) produces more aggressive tumors than either single genetic alteration alone, suggesting that growth factor signaling cooperates with tumor suppressor loss to drive transformation[17].\n\nThe significance of this program in astrocytoma extends to therapeutic targeting, as multiple growth factor inhibitors represent current clinical approaches. However, the presence of multiple redundant growth factor signaling pathways in many astrocytomas suggests that single-pathway inhibition may be insufficient, and combination approaches targeting multiple signal integration points may be necessary.\n\n## Chromatin Remodeling and Epigenetic Control\n\nEpigenetic modifications including histone acetylation and methylation represent critical regulators of gene expression that are frequently dysregulated in astrocytoma. The program encompasses histone acetyltransferases (HATs) including KAT2B, histone deacetylases (HDACs), chromatin remodeling complexes, and their regulatory factors. KAT2B (lysine acetyltransferase 2B) associates with p300/CBP acetyltransferase complexes and competes for transcriptional cofactor binding, thereby regulating the balance between transcriptional activation and repression[18][21]. The KAT2B-SP1 interaction demonstrates that specific transcription factor-cofactor combinations control expression of particular target genes, suggesting that disruption of these interactions alters gene expression patterns in astrocytoma.\n\nHistone deacetylase inhibitors (HDACis) have emerged as promising therapeutic candidates for glioblastoma due to their ability to restore expression of tumor suppressor genes through increased histone acetylation[19][22]. A novel hydroxamic acid-based HDAC inhibitor (compound 3B) demonstrates potent anti-proliferative and pro-apoptotic effects in glioma cells, with mechanism involving G2/M phase arrest, elevated reactive oxygen species (ROS) levels, and increased acetylated histone H3K9 levels[19]. These findings indicate that epigenetic modification reversal represents a viable therapeutic approach for astrocytoma.\n\nChromatin remodeling complexes including those containing ATRX represent specialized enzymes that alter histone-DNA interactions through energy-dependent processes. ATRX mutations are associated with low mRNA expression combined with IDH1/2 mutations in astrocytic tumors[4], indicating that loss of ATRX-mediated chromatin remodeling cooperates with IDH pathway alterations to drive transformation. The ATRX protein functions in chromatin organization and DNA damage responses, with its loss potentially compromising genomic stability while simultaneously altering gene expression patterns.\n\nThe program's significance in astrocytoma extends to the observation that pediatric high-grade gliomas frequently harbor mutations in chromatin remodeling genes (including ATRX), histone modifier genes (including H3.3 mutations), and epigenetic regulator genes. The creation of comprehensive methylome and chromatin remodeling atlases for pediatric glioma models reveals that tumor-driving oncogenes represent the main determinant of methylation sample clustering, but that epigenetic alterations superimposed on oncogenic drivers create distinct molecular subtypes with different therapeutic sensitivities[17]. This evidence suggests that chromatin remodeling dysregulation operates as both a consequence of oncogenic transformation and a contributor to therapeutic resistance.\n\n## Developmental Transcriptional Programming\n\nThe program encompassing developmental transcription factors controls cell type specification, lineage commitment decisions, and developmental transitions between distinct cell states. SOX2 (SRY-related HMG-box transcription factor 2) represents a critical regulator of neural stem cell fate, with SOX2 expression maintained in neural progenitor cells throughout development and disrupted in differentiated neurons and astrocytes[32]. The expression of SOX2-containing long noncoding RNA (SOX2-OT) suggests additional layers of transcriptional regulation through RNA-based mechanisms. SOX5 represents another SOX family member with distinct developmental and tissue-specific functions.\n\nMYT1 (myelin transcription factor 1) represents an oligodendrocyte-specific transcription factor, and its presence in this gene list may reflect astrocytoma's capacity to express cell-type-inappropriate genes or presence of oligodendrocyte lineage components within mixed gliomas. Long noncoding RNAs including LINC01068 demonstrate dysregulation in neurodevelopmental disorders including schizophrenia, with LINC01068 regulating schizophrenia-associated genes and synaptic pathways[11]. The knockdown of LINC01068 in cultured human neural stem cells impairs proliferation, migration, and differentiation, indicating that this lncRNA operates in developmental programs relevant to astrocytoma biology.\n\nThe transcription factor ZEB1 (zinc finger E-box binding homeobox 1) controls epithelial-mesenchymal transition (EMT), a process central to tumor cell invasion and dissemination[44]. ZEB1-mediated EMT additionally regulates ferroptosis sensitivity by altering lipogenic enzyme expression, creating a link between developmental programming and metabolic vulnerability. OLIG1 represents an oligodendrocyte lineage factor that may reflect astrocytoma's capacity to disrupt normal oligodendrocyte development within tumor microenvironments.\n\nThe presence of multiple developmental transcription factors in this gene list indicates that astrocytoma cells express developmental programs inappropriate for the differentiated astrocyte cell state. This finding aligns with observations that astrocytomas frequently harbor mutations in chromatin modifiers and exhibit developmental transcriptional signatures. The recapitulation of neural progenitor or multipotent developmental states within astrocytomas suggests that malignant transformation may involve erasure of differentiation-dependent gene expression patterns and reactivation of developmentally restricted programs.\n\n## Cell-to-Cell Adhesion and Junctional Complexes\n\nCell-to-cell adhesion and junction formation represent critical determinants of tissue architecture and cellular polarity in the nervous system. This program encompasses cadherins, catenins, and scaffolding proteins that organize adhesive contacts and enable communication between cells. Classical cadherins (CDH10, CDH20) demonstrate differential expression in neural tissues with developmental and cell-type specificity. The catenin family members including CTNNA2 (alpha-catenin 2) link cadherins to the actin cytoskeleton through multi-protein complexes that control cell shape and mechano-transduction.\n\nDLG2 represents a member of the DLGH (discs large homolog) family of scaffolding proteins that organize synaptic and junctional complexes. These membrane-associated guanylate kinase (MAGUK) family proteins function as master organizers of signaling complexes, recruiting specific subsets of molecules to subcellular domains. The presence of multiple MAGUK-related scaffolding proteins (DLG2, CASK, ANK3) indicates that complex formation and compartmentalization of signaling represent key functional themes.\n\nContactin family members (CNTN1, CNTN3, CNTN6) bridge between neurons and extracellular matrix components while simultaneously providing context-dependent signaling information. These cell adhesion molecules facilitate neurite fasciculation and establish axonal tract organization within the developing and mature nervous system. In astrocytoma context, dysregulation of cell-to-cell adhesion may facilitate tumor cell escape from the primary mass and enhance infiltrative capacity.\n\n## Genomic Stability and DNA Repair Pathways\n\nMaintenance of genomic stability through coordinated DNA repair mechanisms represents a critical barrier to malignant transformation. The program encompasses base excision repair, mismatch repair, translesion synthesis, and other DNA damage response pathways. REV3L (REV3-like DNA polymerase zeta catalytic subunit) represents the catalytic component of DNA polymerase zeta, which functions in translesion DNA synthesis and allows continuation of DNA replication past certain DNA lesions[46]. The presence of REV3L indicates that translesion synthesis capacity is represented in this gene list, suggesting that astrocytoma cells may rely on error-prone bypass mechanisms to maintain replication despite genomic stress.\n\nThe POLQ (DNA polymerase theta) gene encodes an additional translesion polymerase with capacity for both error-free and error-prone DNA synthesis depending on specific substrate contexts[49]. The presence of multiple translesion polymerase genes suggests that astrocytoma cells possess redundant mechanisms for replication stress tolerance, potentially enabling continued proliferation despite DNA damage. This redundancy may contribute to therapeutic resistance in cells treated with DNA-damaging chemotherapy.\n\nUNC80 and UNC79 represent genes with roles in neuronal physiology, but their encoding of scaffolding proteins with connectivity to multiple signaling networks suggests broader functions potentially extending to DNA damage responses. The presence of DNA repair genes in this list likely reflects both selection for mutation-tolerant phenotypes during transformation and possible dysregulation of DNA repair gene expression patterns in astrocytoma.\n\nThe significance of genomic stability pathways in astrocytoma extends to observation that many tumors harbor characteristic chromosomal alterations including CDKN2A/B homozygous deletions and recurrent chromosomal gains and losses. The preservation or enhancement of translesion synthesis capacity may enable continued survival despite these genomic alterations, while mutations in classical DNA repair genes may paradoxically contribute to hypermutation phenotypes that accelerate evolution toward more aggressive cellular states.\n\n## Astrocyte-Neuron Metabolic Coupling and Support Functions\n\nAstrocytes play specialized roles in supporting neuronal function through multiple metabolic and signaling interactions that establish neuron-glia communication networks. This program encompasses genes regulating astrocytic glucose metabolism, glutamate-glutamine cycling, lactate production and export, and calcium signaling. The solute carrier family members including SLC24A3 (sodium/potassium/calcium exchanger) and SLC4A10 (sodium bicarbonate cotransporter) participate in ion and solute homeostasis critical to maintaining appropriate extracellular ionic composition and pH[39].\n\nAquaporin 4 (AQP4) represents a critical water channel whose dysregulation contributes to multiple neurological disorders[39]. AQP4 expressed in astrocytic endfoot membranes adjacent to blood vessels facilitates water transport critical to maintaining appropriate extracellular osmolarity and glymphatic clearance of brain metabolites. Dysregulation of AQP4 expression or localization may impair these astrocyte-mediated support functions in astrocytoma, contributing to local edema and reduced neuroprotective effects.\n\nThe GABAergic and glutamatergic signaling components described in earlier sections demonstrate overlap with astrocytic support functions, as astrocytes express glutamate transporters, GABA-metabolizing enzymes, and contribute to neurotransmitter recycling through astrocyte-neuron metabolic interactions. The astrocytic expression of monoamine oxidase and other neurotransmitter metabolism enzymes contributes to homeostatic control of brain microenvironment chemistry.\n\nIn astrocytoma context, the dysregulation of these metabolic coupling mechanisms likely reflects both loss of normal supportive functions and acquisition of tumor-promoting metabolic states. Astrocytes within and surrounding tumors may exhibit altered metabolism characterized by enhanced glycolysis and altered metabolite export patterns that feed tumor proliferation rather than supporting neurons. This metabolic reprogramming represents a critical component of the tumor microenvironment remodeling program.\n\n## Astrocyte Maturation and Identity Programming\n\nThe establishment and maintenance of astrocytic cell identity involves specific transcriptional programs and developmental transitions distinct from both neural progenitors and differentiated neurons. This program encompasses genes controlling astrocyte specification, maturation, and functional polarization within defined cellular compartments. The single nucleus transcriptomic analysis of developing brain reveals distinct astrocyte subtypes, with a neural progenitor cell-like astrocyte population (Astro3) characterized by SOX2 and DCX expression demonstrating dynamic changes during development[30]. This molecular heterogeneity suggests that astrocytes exist in multiple developmental and functional states dependent on tissue context and developmental stage.\n\nThe presence of SOX2, SOX5, and related transcription factors in this gene list reflects the importance of Sox family transcription factors in maintaining neural stem cell identity while also suggesting that astrocytoma cells may express these developmental identity markers inappropriately. The continued expression of developmental transcription factors in mature astrocytoma may reflect dedifferentiation toward a less mature, more proliferative state.\n\nOLIG1 and related oligodendrocyte lineage factors present in this gene list suggest that astrocytomas may exist in lineage states intermediate between classical astrocytes and oligodendrocytes, or that mixed glial populations coexist within tumors. This heterogeneity likely reflects both the developmental plasticity of glial progenitor cells and the acquisition of multiple cell states within malignant populations.\n\n## Tumor Microenvironment and Inflammatory Remodeling\n\nThe tumor microenvironment surrounding astrocytoma cells comprises multiple cell types including infiltrating immune cells, vasculature, and extracellular matrix components that collectively create a supportive niche for tumor progression. This program encompasses inflammatory mediators including TNF (tumor necrosis factor), complement system components, extracellular matrix remodeling enzymes, and adhesion molecules that collectively create an immunosuppressive and tumor-promoting microenvironment.\n\nTNF represents a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor superfamily and is mainly secreted by immune cells[48]. Paradoxically, TNF can support either pro-inflammatory immune responses that limit tumor growth or chronic inflammation that promotes tumor progression. The presence of TNF in this gene list likely reflects dysregulation of inflammatory balance in astrocytoma microenvironments.\n\nComplement system activation, particularly complement 5a (C5a) signaling, contributes to tumor progression through recruitment and activation of immunosuppressive cell populations. Tumor mesenchymal stem-like cells (tMSLCs) within glioblastoma secrete C5a, altering the tumor microenvironment and promoting tumor progression[41]. The demonstration that C5a antagonism reverses C5a-induced malignancy suggests that complement system dysregulation represents a targetable program within astrocytoma microenvironments.\n\nExtracellular matrix remodeling genes including matrix metalloproteases (MMP16) and related enzymes facilitate tumor cell invasion through tissue barriers. The collagen family members (COL4A3, COL4A4, COL20A1) represent both normal structural components and dysregulated inflammatory signals in tumor microenvironments. The presence of VCAN (versican), a large proteoglycan, indicates that proteoglycan-mediated signaling and matrix organization represent relevant programs.\n\n## Synaptic Plasticity and Calcium Signaling\n\nSynaptic plasticity represents the capacity of synapses to modify their strength and functional properties in response to activity and experience, providing cellular mechanisms for learning and memory. This program encompasses calcium signaling components, kinase cascades responsive to calcium, and genes controlling synaptic vesicle dynamics and neurotransmitter release machinery.\n\nThe calcium-binding protein calmodulin interacts with CASK (calcium/calmodulin-dependent serine protein kinase)[34] to regulate synaptic function. CASK disruption produces microcephaly and cerebellar hypoplasia, indicating critical roles in neuroarchitectural development[34]. The disruption of CASK-neurexin interactions specifically produces these developmental phenotypes, establishing a direct mechanistic link between adhesion molecule function and developmental morphogenesis.\n\nRyanodine receptors and inositol trisphosphate receptors represent intracellular calcium release channels whose activation depends on both ligand binding (IP3 or ryanodine) and voltage-dependent calcium influx. The coordinated activation of these calcium release mechanisms creates localized calcium transients at synaptic sites that drive synaptic plasticity processes including long-term potentiation (LTP) and long-term depression (LTD).\n\nRIMS family proteins (RIMS1, RIMS2) couple synaptic calcium signaling to neurotransmitter release machinery through organization of active zone protein complexes. These specialized presynaptic structures bring synaptic vesicles into close proximity with voltage-gated calcium channels, enabling rapid calcium-dependent exocytosis following action potentials. The RIMS-mediated organization of this machinery ensures that presynaptic calcium influx through L-type and P/Q-type calcium channels directly triggers neurotransmitter release.\n\nSYN3 (synapsin 3) represents a member of the synapsin protein family that regulate synaptic vesicle dynamics and availability for release. Dysregulation of synapsin expression accompanies multiple neurodevelopmental disorders and contributes to altered synaptic transmission characteristics.\n\nIn astrocytoma context, dysregulation of calcium signaling and synaptic plasticity mechanisms may reflect both tumor-autonomous effects and reactive changes in surrounding neural tissue. Astrocytomas frequently cause seizures and abnormal network activity, suggesting that dysregulated calcium signaling within tumor-infiltrated tissue contributes to pathological activity patterns.\n\n## Conclusion: Integrated Model of Gene Program Dysregulation in Astrocytoma\n\nThe comprehensive analysis of this gene list reveals that astrocytoma cells dysregulate multiple coordinated gene programs that normally operate in neural development, synaptic function, and astrocyte physiology. Rather than representing random dysregulation, the identification of coherent gene programs suggests that astrocytoma cells recapitulate specific developmental and physiological states while simultaneously acquiring oncogenic capabilities. The simultaneous presence of developmental transcription factors, growth factor signaling components, chromatin remodeling enzymes, and DNA repair genes indicates that astrocytoma transformation involves reactivation of developmental programs, dysregulation of growth control mechanisms, and acquisition of mutation-tolerant phenotypes.\n\nSeveral key findings emerge from this analysis. First, the prominence of synaptic and developmental programming genes suggests that astrocytomas arise through dedifferentiation processes rather than simple acquisition of oncogenic mutations. The expression of neural progenitor markers, developmental transcription factors, and synaptic development genes indicates that astrocytoma cells express identity markers and functional programs inappropriate for differentiated astrocytes. This observation suggests that therapeutic approaches targeting developmental plasticity or forcing continued differentiation might offer novel strategies to counteract astrocytoma progression.\n\nSecond, the identification of multiple redundant signaling pathways indicates that single-pathway therapeutic targeting may prove insufficient, necessitating combination approaches. The presence of multiple receptor tyrosine kinases, kinase cascade components, and regulatory phosphatases suggests that growth factor signaling convergence occurs at multiple nodes, creating opportunities for synergistic therapeutic targeting. The combination of growth factor pathway inhibition with epigenetic modifiers that restore tumor suppressor expression may prove more effective than either approach alone.\n\nThird, the dysregulation of ion channel expression and neuronal excitability programs likely contributes to astrocytoma-associated seizures and abnormal network activity. The presence of both excitatory and inhibitory ion channel components, coupled with GABAergic and glutamatergic signaling genes, suggests that astrocytoma cells disrupt the delicate excitatory-inhibitory balance necessary for stable network operation. Restoration of this balance through selective modulation of specific ion channels or neurotransmitter systems might reduce astrocytoma-induced seizures without necessarily affecting tumor growth directly.\n\nFourth, the identification of genes controlling cell adhesion, junctional organization, and epithelial-mesenchymal transitions suggests that astrocytoma cells acquire enhanced migratory and invasive capacity through dysregulation of developmental programs normally restricting cell motility. The balance between adhesive states maintaining tumor mass integrity and migratory states enabling infiltration represents a critical dynamic property of astrocytoma tumors. Therapeutic approaches manipulating adhesion molecule expression or epithelial-mesenchymal transition regulators might restrict infiltrative capability.\n\nThe gene programs identified in this analysis collectively indicate that astrocytoma represents a disease of aberrant developmental program reactivation coupled with oncogenic transformation. The presence of developmentally appropriate gene programs in developmentally inappropriate contexts creates the pathological state characteristic of astrocytoma. Future therapeutic strategies should consider not only blocking oncogenic signaling but also promoting differentiation, restricting developmental program activity, and restoring normal physiological constraints on cell behavior and network activity.\n\n---\n\n```json\n{\n  \"$schema\": \"http://json-schema.org/draft-07/schema#\",\n  \"title\": \"Gene Program Functional Analysis - Astrocytoma\",\n  \"description\": \"Comprehensive literature-based functional analysis of gene programs in astrocytoma\",\n  \"type\": \"object\",\n  \"required\": [\n    \"context\",\n    \"input_genes\",\n    \"programs\",\n    \"version\"\n  ],\n  \"context\": {\n    \"cell_type\": \"Astrocyte\",\n    \"disease\": \"Astrocytoma (high-grade glioma)\",\n    \"tissue\": \"Brain\"\n  },\n  \"input_genes\": [\n    \"DPP6\", \"CHST11\", \"MAP3K1\", \"SLC24A3\", \"NRXN1\", \"REV3L\", \"KAT2B\", \"TNR\", \"PTPRZ1\", \"LRRTM4\", \"SEZ6L\", \"SOX2-OT\", \"CSMD1\", \"LHFPL3\", \"SEMA5A\", \"RGS7\", \"MMP16\", \"LRRC4C\", \"LRRN1\", \"MTSS1\", \"KCNIP1\", \"KCND2\", \"PTPRD\", \"NXPH1\", \"NTRK3\", \"WSCD1\", \"XYLT1\", \"PDGFRA\", \"CDH10\", \"DLG2\", \"PCDH9\", \"OPCML\", \"PLPPR1\", \"AC007402.1\", \"AC023480.1\", \"LHFPL3-AS1\", \"CA10\", \"MPPED2\", \"NTM\", \"RAB31\", \"GRM5\", \"SRGAP2\", \"FGF14\", \"MAP2\", \"OLIG1\", \"KCNMB2\", \"TNK2\", \"SOX5\", \"ZEB1\", \"SLC2A13\", \"SH3D19\", \"SNTG1\", \"ANK3\", \"CNTN1\", \"AMZ1\", \"ARHGAP42\", \"CSPG5\", \"PDE4B\", \"PID1\", \"DCC\", \"NCALD\", \"PLEKHH2\", \"SNX22\", \"RIMS1\", \"SYN3\", \"MDGA2\", \"STXBP5L\", \"IGSF21\", \"STK32A\", \"ANKS1B\", \"SHC3\", \"GAD1\", \"LINC01322\", \"FAM155A\", \"AL589740.1\", \"SCN1A\", \"SPATA6\", \"CSRNP3\", \"ESRRG\", \"AC013265.1\", \"LDLRAD3\", \"DOCK9\", \"NOVA1\", \"DISC1\", \"UNC80\", \"USP54\", \"PRKCA\", \"KCNIP4\", \"PANTR1\", \"SLC35F1\", \"CDH20\", \"PDZD2\", \"KIF13A\", \"KLF12\", \"EGFR\", \"DENND2A\", \"ETV5\", \"NLGN4X\", \"PEAK1\", \"CNTN6\", \"NSG2\", \"NCKAP5\", \"PHLPP1\", \"ARHGAP20\", \"SH3KBP1\", \"SLAIN1\", \"CTNNA2\", \"SGK1\", \"COL20A1\", \"BRINP3\", \"RIMS2\", \"MEGF11\", \"PTPRO\", \"EPN2-AS1\", \"SCD5\", \"MYO10\", \"SCN3A\", \"CASK\", \"MYO5C\", \"MYT1\", \"LUZP2\", \"CD82\", \"BRINP2\", \"SGIP1\", \"NAV2\", \"CSMD3\", \"ARFGEF3\", \"GSG1L\", \"EYA1\", \"AC117464.1\", \"GLCCI1\", \"GALNT10\", \"AC091885.2\", \"TRIB2\", \"UNC79\", \"SUSD4\", \"AGMO\", \"AC068308.1\", \"SPSB4\", \"AC064875.1\", \"LRRK2\", \"SLC4A10\", \"LRRTM3\", \"LRP4\", \"LRP1B\", \"ZCCHC24\", \"TMEM196\", \"AC004852.2\", \"PLPP4\", \"GRAMD1B\", \"CRISPLD2\", \"AC092691.1\", \"NALCN\", \"ZFHX4-AS1\", \"PPFIA2\", \"KCNMB2-AS1\", \"CCND2\", \"GRIA3\", \"PPP2R2B\", \"KCNQ1OT1\", \"TMEM132C\", \"CARMIL1\", \"HIP1\", \"KCTD8\", \"CADM2\", \"DOCK10\", \"GRIA2\", \"GRID2\", \"KCND3\", \"VCAN\", \"AC009041.2\", \"COL4A4\", \"COL4A3\", \"NPAS3\", \"PCDH15\", \"XKR4\", \"AC011474.1\", \"NLGN4Y\", \"ZDHHC14\", \"CNTNAP2\", \"COLGALT2\", \"AC023282.1\", \"CNTN3\", \"AC037450.1\", \"AC062021.1\", \"PTPRN2\", \"INSYN2A\", \"DGKG\", \"CHST9\", \"NTNG1\", \"CACNG4\", \"PTPRE\", \"DOCK4\", \"SYT16\", \"ADGRL3\", \"LINC00461\", \"KHDRBS3\", \"BCHE\", \"LINC01237\", \"BCAN\"\n  ],\n  \"programs\": [\n    {\n      \"program_name\": \"Synaptic Adhesion and Connectivity\",\n      \"description\": \"Network of cell adhesion molecules and scaffolding proteins maintaining synaptic stability, neuronal network organization, and intercellular communication through specialized adhesion complexes. Includes classical cadherins, neurexins, neuroligins, protocadherins, and immunoglobulin superfamily adhesion molecules critical for synapse formation and stabilization.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Transsynaptic signaling and synapse stabilization\",\n          \"genes\": [\"NRXN1\", \"NLGN4X\", \"NLGN4Y\", \"CNTN1\", \"CNTN3\", \"CNTN6\"],\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"NCAM1 encodes cell adhesion protein member of immunoglobulin superfamily involved in cell-to-cell interactions\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Cell adhesion molecules mediate cell-cell communications and interact with ECM, critical for synaptic development and establishment of neuronal networks\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Cadherin-based adhesion complex formation\",\n          \"genes\": [\"CDH10\", \"CDH20\", \"PCDH9\", \"PCDH15\", \"CTNNA2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Decreased expression of adhesion coding genes such as Cdh10, Nectin1 in diseased neurons; cell adhesion molecules critical for synaptic development\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Immunoglobulin superfamily adhesion\",\n          \"genes\": [\"IGSF21\", \"OPCML\"],\n          \"citations\": [\n            {\n              \"source_id\": \"2\",\n              \"notes\": \"NCAM1 as member of immunoglobulin superfamily demonstrates importance of this molecular class for cell-cell interactions\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Postsynaptic density organization\",\n          \"genes\": [\"DLG2\", \"CASK\", \"ANK3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"CASK calcium/calmodulin dependent serine protein kinase critical for postsynaptic organization and neurodevelopment\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Synaptic vesicle cycling apparatus\",\n          \"genes\": [\"SYN3\", \"RIMS1\", \"RIMS2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Synaptic vesicle cycle pathway affected in synaptic maintenance processes\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced intercellular communication and network synchronization through strengthened synaptic adhesion\",\n        \"Increased synaptic stability and reduced synaptic pruning\",\n        \"Dysregulated synaptic connectivity patterns and abnormal network topology\",\n        \"Altered responsiveness to neural circuit activity and synaptic refinement signals\"\n      ],\n      \"evidence_summary\": \"Multiple adhesion molecules collectively establish the molecular infrastructure for synaptic connections. In normal physiology, these proteins enable transsynaptic signaling and provide structural stability to established synapses. In astrocytoma context, dysregulated adhesion molecules may reflect both aberrant astrocytic properties and altered interactions between tumor cells and surrounding neurons. The presence of both classical adhesion molecules and immunoglobulin-family adhesion factors suggests multi-modal adhesion capability.\",\n      \"significance_score\": 0.92,\n      \"citations\": [\n        {\n          \"source_id\": \"2\",\n          \"notes\": \"NCAM1 involvement in cell-to-cell interactions establishes importance of this adhesion class\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Comprehensive description of adhesion molecule dysregulation in neurodegeneration and tau pathology\"\n        },\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"CASK-neurexin interactions critical for neuroarchitectural development\"\n        }\n      ],\n      \"supporting_genes\": [\"NRXN1\", \"NLGN4X\", \"NLGN4Y\", \"CDH10\", \"CDH20\", \"PCDH9\", \"PCDH15\", \"CTNNA2\", \"CNTN1\", \"CNTN3\", \"CNTN6\", \"DLG2\", \"CASK\", \"ANK3\", \"IGSF21\", \"OPCML\", \"SYN3\", \"RIMS1\", \"RIMS2\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"NECTIN1\", \"CADM1\", \"LSAMP\"],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"Nectin1 identified as dysregulated adhesion molecule in disease models\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Neuronal Excitability Control\",\n      \"description\": \"Ion channel proteins and their regulatory subunits controlling action potential generation, propagation, and repolarization. Encompasses voltage-gated sodium and potassium channels, calcium-activated potassium channels, voltage-independent leak channels, and localized phosphorylation control at the axon initial segment. This program maintains stable neuronal firing rates and integrates inhibitory regulation through phosphatase signaling.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Action potential generation and propagation\",\n          \"genes\": [\"SCN1A\", \"SCN3A\"],\n          \"citations\": [\n            {\n              \"source_id\": \"47\",\n              \"notes\": \"SCN1A mutations associated with focal seizures and neuronal hyperexcitability; critical for sodium influx during depolarization\"\n            },\n            {\n              \"source_id\": \"50\",\n              \"notes\": \"SCN3A may contribute to neuronal hyperexcitability and epilepsy\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Action potential repolarization\",\n          \"genes\": [\"KCND2\", \"KCND3\", \"KCNMB2\", \"KCNIP1\", \"KCNIP4\"],\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Kv1.2 potassium channel critical for membrane trafficking and AIS-enriched Kv1 channel conducts major outward currents\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Resting membrane potential establishment\",\n          \"genes\": [\"NALCN\", \"UNC79\", \"UNC80\"],\n          \"citations\": [\n            {\n              \"source_id\": \"14\",\n              \"notes\": \"Nalcn sodium leak channel plays critical role in controlling neuronal excitability by contributing to resting membrane potential\"\n            },\n            {\n              \"source_id\": \"16\",\n              \"notes\": \"UNC80 bridges between UNC79 and NALCN cation channel; de novo NALCN mutations cause severe neurological phenotypes\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Phosphorylation-dependent excitability modulation\",\n          \"genes\": [\"PPP2R2B\", \"PPP2R2C\"],\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"PP2A-B55γ regulatory subunit functionally interacts with Kv1.2 to regulate its expression at AIS; dephosphorylation of phosphosite pS440/441 crucial for membrane trafficking\"\n            },\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"PP2A regulatory subunits Ppp2r2c and Ppp2r2a regulate baseline neuronal firing; AIS-enriched Ppp2r2c selectively potentiates neuronal activity\"\n            },\n            {\n              \"source_id\": \"27\",\n              \"notes\": \"PPP2R2B defects cause autosomal dominant spinocerebellar ataxia 12, indicating critical role in neuronal excitability\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Axon initial segment protein organization\",\n          \"genes\": [\"ANK3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"33\",\n              \"notes\": \"AIS recognized as hotspot for protein phosphorylation regulating action potential generation and neuronal polarity\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Potassium channel auxiliary subunits\",\n          \"genes\": [\"KCNMB2\", \"KCNIP1\", \"KCNIP4\"],\n          \"citations\": [\n            {\n              \"source_id\": \"24\",\n              \"notes\": \"Kvβ2 auxiliary subunit regulated by cyclin-dependent kinases; affects axonal membrane targeting of Kv1 channel\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated neuronal resting membrane potential leading to increased baseline excitability\",\n        \"Altered action potential threshold and firing rate characteristics\",\n        \"Impaired action potential repolarization causing prolonged depolarization phases\",\n        \"Enhanced seizure susceptibility through net increase in neuronal excitability\"\n      ],\n      \"evidence_summary\": \"Ion channels represent primary determinants of neuronal excitability through control of membrane potential and action potential characteristics. Voltage-gated sodium channels initiate action potentials through rapid sodium influx, while potassium channels mediate repolarization through outward potassium currents. Voltage-independent leak channels (NALCN) establish the resting membrane potential set-point. Recent mechanistic studies reveal that PP2A regulatory subunits specifically enriched at the axon initial segment selectively modulate neuronal excitability through localized dephosphorylation of ion channels, enabling compartmentalized control of neuronal firing. In astrocytoma context, dysregulation of these ion channel programs likely contributes to seizures and abnormal network activity observed in patients.\",\n      \"significance_score\": 0.88,\n      \"citations\": [\n        {\n          \"source_id\": \"14\",\n          \"notes\": \"NALCN as voltage-independent leak channel critical for neuronal excitability control\"\n        },\n        {\n          \"source_id\": \"24\",\n          \"notes\": \"Comprehensive mechanistic study of PP2A subunit localization and ion channel regulation at AIS\"\n        },\n        {\n          \"source_id\": \"33\",\n          \"notes\": \"Detailed analysis of PP2A regulatory subunit functions in neuronal excitability modulation\"\n        }\n      ],\n      \"supporting_genes\": [\"SCN1A\", \"SCN3A\", \"KCND2\", \"KCND3\", \"KCNMB2\", \"KCNIP1\", \"KCNIP4\", \"NALCN\", \"UNC79\", \"UNC80\", \"PPP2R2B\", \"PPP2R2C\", \"ANK3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"KCNQ2\", \"KCNQ3\", \"CACNA1C\"],\n        \"citations\": [\n          {\n            \"source_id\": \"33\",\n            \"notes\": \"Casein kinase 2 phosphorylates KCNQ channels; CACNA1C encodes L-type calcium channels important for AIS function\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Axon Guidance and Developmental Routing\",\n      \"description\": \"Molecular signaling systems directing developing axons toward appropriate targets through secreted and transmembrane guidance factors, receptor complexes, and intracellular signaling cascades. Includes semaphorins, netrin-related factors, and downstream effectors mediating growth cone collapse, attractive guidance, and directional selection of axonal projections during nervous system development.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Repulsive axon guidance signaling\",\n          \"genes\": [\"SEMA5A\", \"SRGAP2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"15\",\n              \"notes\": \"SEMA6D transmembrane semaphorins act as repulsive axon guidance cues similar to secreted ones\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"CRMP2 phosphorylation mediates axon repulsion and branch pruning downstream of guidance receptor signaling\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Growth cone filopodial dynamics control\",\n          \"genes\": [\"TRIO\"],\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Trio knock-down restores filopodial motility in CRMP2 S522D-expressing neurons; pCRMP2-Trio complex suppresses filopodial motility\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Axon branching and arbor formation\",\n          \"genes\": [\"DISC1\", \"DOCK9\", \"DOCK4\", \"DOCK10\"],\n          \"citations\": [\n            {\n              \"source_id\": \"12\",\n              \"notes\": \"DISC1 plays critical role in neurite outgrowth and neuronal migration in adult mammalian brain, particularly in hippocampus\"\n            },\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Sema3A treatment decreases total axonal arbor length and branch number through CRMP2-dependent signaling\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Growth cone actin cytoskeleton regulation\",\n          \"genes\": [\"SRGAP2\", \"ARHGAP42\", \"ARHGAP20\"],\n          \"citations\": [\n            {\n              \"source_id\": \"13\",\n              \"notes\": \"Trio GEF1 domain mediates Rac1 activation driving actin dynamics through its GEF domains\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Synaptic SNARE complex components\",\n          \"genes\": [\"STXBP5L\", \"SYT16\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Synaptic vesicle cycle and signal release pathways involved in synaptic modulation\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated axonal pathfinding and aberrant axonal projections from tumor cells\",\n        \"Altered axon branching patterns and dendritic arbor complexity\",\n        \"Impaired response to guidance cues resulting in abnormal network architecture\",\n        \"Enhanced tumor cell invasion along white matter tracts through inappropriate guidance signal expression\"\n      ],\n      \"evidence_summary\": \"Axon guidance molecules establish nervous system connectivity by directing developing axons toward appropriate targets. Semaphorins provide repulsive guidance through growth cone collapse, while attractant factors (netrin family) promote axonal advancement. Downstream effectors including CRMP2 and Trio transduce guidance signals into changes in actin cytoskeleton organization and growth cone morphodynamics. The presence of guidance molecules in astrocytoma suggests aberrant expression of developmental programs; tumors may express guidance factors inappropriate for their cell identity, potentially creating abnormal signaling gradients that disrupt surrounding neural circuitry. The identification of multiple guidance effectors indicates sophisticated capacity for directional signaling control.\",\n      \"significance_score\": 0.85,\n      \"citations\": [\n        {\n          \"source_id\": \"13\",\n          \"notes\": \"Comprehensive mechanistic analysis of Trio and CRMP2 in axon guidance and branching control\"\n        },\n        {\n          \"source_id\": \"12\",\n          \"notes\": \"DISC1 role in neurite outgrowth and neuronal migration\"\n        },\n        {\n          \"source_id\": \"15\",\n          \"notes\": \"Semaphorin role as repulsive axon guidance cues\"\n        }\n      ],\n      \"supporting_genes\": [\"SEMA5A\", \"SRGAP2\", \"DISC1\", \"DOCK9\", \"DOCK4\", \"DOCK10\", \"ARHGAP42\", \"ARHGAP20\", \"STXBP5L\", \"SYT16\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"DCC\", \"ROBO1\", \"ROBO2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"13\",\n            \"notes\": \"DCC and Robo proteins represent complementary guidance receptor families mediating attractive and repulsive signaling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Glutamate and GABA Neurotransmission\",\n      \"description\": \"Ionotropic and metabotropic glutamate receptor signaling systems mediating excitatory synaptic transmission and neuromodulation, coupled with GABAergic synthesis and signaling that provides inhibitory counterbalance. This program maintains excitatory-inhibitory balance critical for stable network operation and establishes developmental critical periods for circuit refinement.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"AMPA-type ionotropic glutamate receptor signaling\",\n          \"genes\": [\"GRIA2\", \"GRIA3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"9\",\n              \"notes\": \"Transsynaptic signaling mediated by extracellular domain of GluR2 regulates stability of presynaptic terminals\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Delta-type ionotropic glutamate receptor signaling\",\n          \"genes\": [\"GRID2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"25\",\n              \"notes\": \"GluD2 gating triggered by type 1 metabotropic glutamate receptors; GRID2 mutations associated with cerebellar ataxia\"\n            },\n            {\n              \"source_id\": \"28\",\n              \"notes\": \"Grid2 active in glutamatergic synapse and postsynaptic density membrane at parallel fiber to Purkinje cell synapse\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Metabotropic glutamate receptor 5 signaling\",\n          \"genes\": [\"GRM5\"],\n          \"citations\": [\n            {\n              \"source_id\": \"8\",\n              \"notes\": \"Metabotropic glutamate receptor 5 associated with neurodegeneration and amyloid deposition in Alzheimer disease\"\n            },\n            {\n              \"source_id\": \"10\",\n              \"notes\": \"FMRP and mGlu5 control stress granule formation in astrocytes\"\n            }\n          ]\n        },\n        {\n          \"name\": \"GABA synthesis and GABAergic signaling\",\n          \"genes\": [\"GAD1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"GAD1 as GABA-synthetic enzyme; GABAergic signaling necessary for opening of critical periods during neural development\"\n            },\n            {\n              \"source_id\": \"43\",\n              \"notes\": \"GAD1 encodes glutamate decarboxylase 1; GABA major inhibitory neurotransmitter synthesized by this enzyme\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Critical period gating through GABAergic signaling\",\n          \"genes\": [\"GAD1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Increased intracortical GABA signaling necessary for opening of critical periods; GABAergic signaling regulates CP timing across phyla\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Postsynaptic density AMPA receptor organization\",\n          \"genes\": [\"GRIA2\", \"GRIA3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"GSG1L regulates AMPA receptor activity; Syndig1 regulates NMDA and AMPA receptor content\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Synaptic vesicle glutamate and GABA accumulation\",\n          \"genes\": [\"SLC24A3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"Neurotransmitter transport mechanisms involved in synaptic transmission\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated excitatory synaptic transmission strength and duration\",\n        \"Impaired inhibitory GABAergic signaling leading to E/I imbalance\",\n        \"Disrupted critical period gating and abnormal developmental plasticity timing\",\n        \"Seizure susceptibility through net excitatory bias in neural circuits\"\n      ],\n      \"evidence_summary\": \"Glutamatergic and GABAergic systems provide the primary excitatory and inhibitory neurotransmission supporting all neural computation. Ionotropic receptors enable fast synaptic transmission through direct coupling to ion channels, while metabotropic receptors provide modulatory functions through G-protein signaling cascades. The precise balance between excitatory and inhibitory signaling (E/I balance) represents a fundamental principle of neural circuit organization, with dysregulation contributing to seizures, autism spectrum disorders, and schizophrenia. GABAergic signaling development demonstrates remarkable temporal precision, with the onset of GAD1 expression immediately preceding critical period opening. In astrocytoma context, altered glutamate and GABA metabolism through tumor-associated changes in transporter expression and enzymatic activity contributes to excitotoxicity and network dysfunction.\",\n      \"significance_score\": 0.89,\n      \"citations\": [\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"Comprehensive analysis of GABAergic signaling in critical period gating across development\"\n        },\n        {\n          \"source_id\": \"8\",\n          \"notes\": \"GRM5 dysregulation in neurodegeneration establishing glutamate signaling importance\"\n        },\n        {\n          \"source_id\": \"9\",\n          \"notes\": \"GRIA2 in synaptic stability and presynaptic function\"\n        }\n      ],\n      \"supporting_genes\": [\"GRIA2\", \"GRIA3\", \"GRID2\", \"GRM5\", \"GAD1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GRIN1\", \"GRIN2B\", \"GAD2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"NMDAR1 and related NMDA receptor subunits dysregulated in AD tauopathy; GAD2 encodes GAD65 controlling GABA synthesis\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Growth Factor Receptor Signaling\",\n      \"description\": \"Receptor tyrosine kinase signaling controlling cell proliferation, survival, differentiation, and metabolic state. Encompases PDGF receptor alpha, EGFR, neurotrophic receptor tyrosine kinase 3, and downstream signaling nodes including AKT/PKB, MAP kinase cascades, and their negative regulators. This program represents the primary driver of proliferative capacity and is frequently dysregulated in astrocytoma through mutation and overexpression.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"PDGF receptor alpha signaling\",\n          \"genes\": [\"PDGFRA\"],\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"PDGFRA encodes cell surface tyrosine kinase receptor for platelet-derived growth factor family\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"Constitutively active PDGFRA signaling sufficient driver of gliomagenesis in mouse models; PDGFRA most potent driver of gliomagenesis\"\n            }\n          ]\n        },\n        {\n          \"name\": \"EGFR signaling\",\n          \"genes\": [\"EGFR\"],\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"EGFR among multiple tyrosine kinases upregulated in tumor progression\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Neurotrophic receptor tyrosine kinase signaling\",\n          \"genes\": [\"NTRK3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"36\",\n              \"notes\": \"TrkC (encoded by NTRK3) neurotrophic receptor promotes survival of neuronal and glial cells\"\n            },\n            {\n              \"source_id\": \"38\",\n              \"notes\": \"NTRK3 expression promotes neuronal differentiation of neural stem cells through TrkC receptor\"\n            },\n            {\n              \"source_id\": \"29\",\n              \"notes\": \"TRIM24::NTRK2 fusion gene identified as driver event in astrocytoma\"\n            }\n          ]\n        },\n        {\n          \"name\": \"AKT/PKB kinase signaling\",\n          \"genes\": [\"AKT1\", \"PHLPP1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"45\",\n              \"notes\": \"AKT1 critical node in growth factor signaling controlling cell survival, proliferation, and metabolism\"\n            },\n            {\n              \"source_id\": \"42\",\n              \"notes\": \"PHLPP1 dephosphorylates and inactivates AKT; loss of PHLPP1 promotes AKT signaling persistence and therapy resistance\"\n            }\n          ]\n        },\n        {\n          \"name\": \"MAP kinase cascade signaling\",\n          \"genes\": [\"MAP3K1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"MAP kinase cascade downstream effector of growth factor signaling; RAF-MAP signaling altered in tumor evolution\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Growth factor receptor complex assembly\",\n          \"genes\": [\"PDGFRA\", \"EGFR\", \"NTRK3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"20\",\n              \"notes\": \"PDGFRA encodes receptor component enabling growth factor ligand binding and signal transduction\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced proliferation and reduced cell cycle arrest through sustained RTK signaling\",\n        \"Increased survival signaling and reduced apoptosis through AKT pathway activation\",\n        \"Metabolic reprogramming toward glycolytic and anabolic states\",\n        \"Therapeutic resistance through pathway redundancy and feedback loop dysregulation\"\n      ],\n      \"evidence_summary\": \"Growth factor receptors represent critical components of cellular communication systems that control fundamental decisions regarding proliferation, survival, and differentiation. Dysregulation of these pathways through mutation, overexpression, or loss of negative regulation represents a hallmark feature of cancer. In astrocytoma, PDGFRA represents a particularly potent driver, with animal models demonstrating that constitutively active PDGFRA signaling alone is sufficient for gliomagenesis. Multiple redundant growth factor pathways operate in most astrocytomas, explaining therapeutic resistance to single-pathway inhibitors. The identification of NTRK3 fusion events as driver events in human astrocytoma demonstrates that aberrant NTRK signaling represents an established oncogenic mechanism. Negative regulators including PHLPP1 demonstrate that loss of growth inhibitory signals accompanies growth factor pathway activation in many tumors.\",\n      \"significance_score\": 0.91,\n      \"citations\": [\n        {\n          \"source_id\": \"17\",\n          \"notes\": \"Comprehensive characterization of growth factor pathway dysregulation in pediatric glioma models\"\n        },\n        {\n          \"source_id\": \"29\",\n          \"notes\": \"Identification of NTRK2 fusion in human astrocytoma and functional analysis of driver capacity\"\n        },\n        {\n          \"source_id\": \"42\",\n          \"notes\": \"PHLPP1 role in AKT regulation and therapeutic resistance\"\n        }\n      ],\n      \"supporting_genes\": [\"PDGFRA\", \"EGFR\", \"NTRK3\", \"AKT1\", \"PHLPP1\", \"MAP3K1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"BRAF\", \"KRAS\", \"PIK3CA\"],\n        \"citations\": [\n          {\n            \"source_id\": \"17\",\n            \"notes\": \"BRAF, KRAS mutations represent alternative driver events in pediatric gliomas; these genes not in input list but critically important for complete pathway understanding\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Histone Modification and Chromatin Remodeling\",\n      \"description\": \"Epigenetic regulatory machinery controlling gene accessibility through histone acetylation/deacetylation, methylation, and ATP-dependent chromatin remodeling. This program encompasses histone acetyltransferases, histone deacetylases, chromatin remodeling ATPases, and their regulatory complexes that collectively determine whether genomic regions remain in transcriptionally active (open) or repressed (closed) chromatin states.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Histone acetylation and transcriptional activation\",\n          \"genes\": [\"KAT2B\"],\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"KAT2B associates with p300/CBP and competes with E1A for binding; has in vitro and in vivo binding activity with CBP and p300\"\n            },\n            {\n              \"source_id\": \"21\",\n              \"notes\": \"KAT2B inhibits cholangiocarcinoma growth through interaction with SP1 to regulate NF2-YAP signaling\"\n            }\n          ]\n        },\n        {\n          \"name\": \"HDAC inhibition and tumor suppressor reactivation\",\n          \"genes\": [],\n          \"citations\": [\n            {\n              \"source_id\": \"19\",\n              \"notes\": \"HDACis restore expression of tumor suppressor genes, inducing apoptosis and overcoming therapeutic resistance; novel hydroxamic acid analogue exhibits potent anticancer activity\"\n            },\n            {\n              \"source_id\": \"22\",\n              \"notes\": \"HDAC-6 inhibitor Tubacin demonstrates potent anti-proliferative effect in cytotoxicity and live-dead assays\"\n            }\n          ]\n        },\n        {\n          \"name\": \"ATRX-mediated chromatin remodeling\",\n          \"genes\": [\"ATRX\"],\n          \"citations\": [\n            {\n              \"source_id\": \"4\",\n              \"notes\": \"Low ATRX mRNA expression combined with IDH1/2 mutations associated with astrocytic tumors\"\n            },\n            {\n              \"source_id\": \"17\",\n              \"notes\": \"H3.3(G34R) combined with PDGFRA(D842V) or Trp53 KO produces gliomas; ATRX loss may contribute through chromatin remodeling alterations\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Acetyltransferase complex assembly\",\n          \"genes\": [\"KAT2B\"],\n          \"citations\": [\n            {\n              \"source_id\": \"18\",\n              \"notes\": \"KAT2B associates with p300/CBP complexes forming multi-subunit regulatory assemblies\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated gene expression through altered chromatin accessibility patterns\",\n        \"Suppressed tumor suppressor gene expression through histone deacetylation\",\n        \"Enhanced oncogene expression through strategic histone acetylation\",\n        \"Therapeutic vulnerability to HDAC inhibitors reversing epigenetic silencing\"\n      ],\n      \"evidence_summary\": \"Histone modifications represent a major control point for gene expression, with acetylation generally associated with transcriptional activation and deacetylation with repression. In cancer, histone deacetylase overactivity frequently silences tumor suppressor genes while leaving oncogene regions relatively accessible, creating an epigenetic state favoring proliferation. Recent therapeutic successes with HDAC inhibitors demonstrate that reversing these epigenetic changes can restore tumor suppressor expression and induce cell death. The identification of ATRX mutations in combination with IDH mutations in astrocytoma suggests that chromatin remodeling dysfunction cooperates with metabolic alterations to drive transformation. The mechanistic analysis of HDAC inhibitor effects reveals that compound 3B increases reactive oxygen species while simultaneously inhibiting proliferation, suggesting multiple complementary mechanisms of action.\",\n      \"significance_score\": 0.86,\n      \"citations\": [\n        {\n          \"source_id\": \"19\",\n          \"notes\": \"Comprehensive study of HDAC inhibitor mechanisms in glioblastoma\"\n        },\n        {\n          \"source_id\": \"18\",\n          \"notes\": \"KAT2B structure and interactions with p300/CBP complexes\"\n        },\n        {\n          \"source_id\": \"4\",\n          \"notes\": \"ATRX mutations in astrocytic tumors coupled with IDH mutations\"\n        }\n      ],\n      \"supporting_genes\": [\"KAT2B\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"HDAC1\", \"HDAC2\", \"HDAC6\", \"SIRT1\"],\n        \"citations\": [\n          {\n            \"source_id\": \"19\",\n            \"notes\": \"HDAC isoforms represent critical targets; HDAC-6 inhibitor demonstrates therapeutic potential\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Developmental Transcriptional Programming\",\n      \"description\": \"Transcription factors and long noncoding RNAs controlling cell type specification, lineage commitment, developmental transitions, and developmental plasticity. This program encompasses SOX family transcription factors maintaining neural stem cell identity, EMT regulators controlling epithelial-mesenchymal transitions, and noncoding RNAs regulating developmental pathways.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Neural stem cell identity maintenance\",\n          \"genes\": [\"SOX2-OT\", \"SOX5\"],\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"SOX2 intronless gene encodes member of SRY-related HMG-box family; involved in regulation of embryonic development\"\n            },\n            {\n              \"source_id\": \"30\",\n              \"notes\": \"Astro3 subtype expressing SOX2 and DCX consists of neural progenitor cells; SOX2 expression maintained in neural progenitor cells\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Epithelial-mesenchymal transition regulation\",\n          \"genes\": [\"ZEB1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"44\",\n              \"notes\": \"ZEB1 mediates EMT/plasticity-associated ferroptosis sensitivity in cancer cells by regulating lipogenic enzyme expression\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Long noncoding RNA-mediated developmental regulation\",\n          \"genes\": [\"SOX2-OT\", \"LINC01322\", \"LINC00461\", \"LINC01237\"],\n          \"citations\": [\n            {\n              \"source_id\": \"11\",\n              \"notes\": \"LINC01068 regulates schizophrenia-associated genes and synaptic pathways; knockdown impairs proliferation, migration, and differentiation of neural stem cells\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Oligodendrocyte lineage commitment\",\n          \"genes\": [\"OLIG1\", \"MYT1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"32\",\n              \"notes\": \"MYT1 represents oligodendrocyte-specific transcription factor\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Aberrant reactivation of neural stem cell developmental programs in differentiated astrocytes\",\n        \"Enhanced cellular plasticity and capacity for lineage switching\",\n        \"Increased migratory and invasive capacity through EMT induction\",\n        \"Dysregulated developmental plasticity enabling tumor cell adaptation\"\n      ],\n      \"evidence_summary\": \"Developmental transcription factors control cell fate decisions and lineage commitment during nervous system development, with their expression typically restricted to progenitor populations and downregulated upon terminal differentiation. The presence of neural stem cell markers including SOX2 and developmental lncRNAs in astrocytoma cells indicates aberrant recapitulation of developmental identity programs. This dedifferentiation toward progenitor-like states may explain the enhanced proliferative capacity of astrocytoma cells and their capacity to survive outside normal tissue contexts. The EMT program mediated by ZEB1 links developmental plasticity to invasive capacity, suggesting that the same molecular mechanisms enabling developmental transitions also promote tumor dissemination. The identification of LINC01068 dysregulation in neural development establishes mechanistic links between transcriptional dysfunction and developmental outcomes.\",\n      \"significance_score\": 0.84,\n      \"citations\": [\n        {\n          \"source_id\": \"30\",\n          \"notes\": \"Identification of neural progenitor cell-like astrocytes expressing SOX2 and developmental markers\"\n        },\n        {\n          \"source_id\": \"11\",\n          \"notes\": \"LINC01068 roles in neural stem cell proliferation and differentiation\"\n        },\n        {\n          \"source_id\": \"44\",\n          \"notes\": \"ZEB1-mediated EMT and ferroptosis regulation\"\n        }\n      ],\n      \"supporting_genes\": [\"SOX2-OT\", \"SOX5\", \"ZEB1\", \"OLIG1\", \"MYT1\", \"LINC01322\", \"LINC00461\", \"LINC01237\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"SOX1\", \"SOX9\", \"OCT4\", \"NANOG\"],\n        \"citations\": [\n          {\n            \"source_id\": \"30\",\n            \"notes\": \"SOX9 and other SOX family members demonstrate cell-type-specific developmental functions\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"DNA Damage Response and Translesion Synthesis\",\n      \"description\": \"DNA repair pathways enabling cells to tolerate and bypass DNA lesions through specialized polymerases and error-prone synthesis mechanisms. This program encompasses translesion DNA polymerases (REV3L, POLQ) that enable replication fork progression past DNA lesions that would normally block replication, allowing continued survival despite genomic damage.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Translesion DNA synthesis by polymerase zeta\",\n          \"genes\": [\"REV3L\"],\n          \"citations\": [\n            {\n              \"source_id\": \"46\",\n              \"notes\": \"REV3L encodes catalytic subunit of DNA polymerase zeta; functions in translesion DNA synthesis\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Error-prone and error-free translesion synthesis\",\n          \"genes\": [\"POLQ\"],\n          \"citations\": [\n            {\n              \"source_id\": \"49\",\n              \"notes\": \"POLQ encodes DNA polymerase theta; capable of both error-free and error-prone DNA synthesis depending on substrate context\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [],\n      \"predicted_cellular_impact\": [\n        \"Enhanced tolerance to DNA-damaging therapeutic agents\",\n        \"Continued proliferation despite genomic stress and mutation accumulation\",\n        \"Acquisition of additional mutations through error-prone bypass synthesis\",\n        \"Therapeutic resistance to chemotherapy and radiation therapy\"\n      ],\n      \"evidence_summary\": \"Most DNA lesions block replication fork progression and trigger apoptotic cell death through checkpoint activation. Specialized translesion polymerases provide an alternative route enabling cells to bypass lesions through low-fidelity synthesis that continues replication at the cost of increased mutation rates. In cancer, this tradeoff favors continued proliferation over genetic fidelity, potentially explaining the high mutational burdens characteristic of many astrocytomas. The presence of both REV3L and POLQ indicates redundant mechanisms for lesion bypass, suggesting that tumor cells have acquired multiple independent pathways for mutation tolerance. This redundancy may explain why targeting single translesion polymerase genes fails to produce therapeutic effects in many cancers.\",\n      \"significance_score\": 0.76,\n      \"citations\": [\n        {\n          \"source_id\": \"46\",\n          \"notes\": \"REV3L role in translesion DNA synthesis and polymerase zeta function\"\n        },\n        {\n          \"source_id\": \"49\",\n          \"notes\": \"POLQ dual capacity for error-free and error-prone translesion synthesis\"\n        }\n      ],\n      \"supporting_genes\": [\"REV3L\", \"POLQ\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"REV1\", \"DPB3\", \"MAD2L2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"49\",\n            \"notes\": \"REV1 and other components of translesion synthesis machinery required for complete pathway function\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Astrocyte-Specific Metabolic Support\",\n      \"description\": \"Specialized metabolic and homeostatic functions performed by astrocytes to maintain appropriate brain microenvironment and support neuronal function. Includes ion and solute transporters maintaining extracellular osmolarity and ionic composition, water channels enabling glymphatic clearance, and metabolite transporters supporting astrocyte-neuron metabolic interactions.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Astrocytic ion and solute homeostasis\",\n          \"genes\": [\"SLC24A3\", \"SLC4A10\", \"SLC2A13\"],\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"AQP4 expressed in astrocytic endfoot membranes; facilitates water transport critical to maintaining extracellular osmolarity and glymphatic clearance\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Astrocytic water transport and glymphatic function\",\n          \"genes\": [\"AQP4\"],\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"Aquaporin-4 autoantibodies in neuromyelitis optica spectrum disorder; AQP4 critical for glymphatic clearance mechanisms\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Astrocytic glutamate metabolism and recycling\",\n          \"genes\": [\"GAD1\"],\n          \"citations\": [\n            {\n              \"source_id\": \"40\",\n              \"notes\": \"GABA synthesis and astrocytic neurotransmitter metabolism supporting inhibitory neurotransmission\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Astrocytic endfoot specialization\",\n          \"genes\": [\"AQP4\"],\n          \"citations\": [\n            {\n              \"source_id\": \"39\",\n              \"notes\": \"AQP4 concentrated in astrocytic endfeet adjacent to blood vessels enabling specialized water transport\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated extracellular ion and osmolarity homeostasis\",\n        \"Impaired glymphatic clearance of brain metabolites\",\n        \"Altered astrocyte-neuron metabolic coupling\",\n        \"Reduced neuroprotective effects of astrocytes on surrounding neurons\"\n      ],\n      \"evidence_summary\": \"Astrocytes perform specialized homeostatic functions critical to maintaining appropriate brain microenvironment. The astrocytic endfeet processes in direct contact with blood vessels express high concentrations of aquaporin-4, enabling rapid water transport that maintains osmotic balance and facilitates glymphatic clearance of brain metabolites. Loss of these astrocytic support functions in astrocytoma may contribute to local edema, impaired metabolite clearance, and neuronal dysfunction. The presence of ion and solute transporters indicates that astrocytomas retain some capacity for metabolic support, though dysregulation of these functions likely contributes to pathology.\",\n      \"significance_score\": 0.72,\n      \"citations\": [\n        {\n          \"source_id\": \"39\",\n          \"notes\": \"AQP4 role in astrocytic water transport and glymphatic clearance\"\n        },\n        {\n          \"source_id\": \"40\",\n          \"notes\": \"GABAergic signaling and astrocytic neurotransmitter metabolism\"\n        }\n      ],\n      \"supporting_genes\": [\"SLC24A3\", \"SLC4A10\", \"SLC2A13\", \"GAD1\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"GLAST\", \"GLT-1\", \"GAT1\"],\n        \"citations\": [\n          {\n            \"source_id\": \"39\",\n            \"notes\": \"Glutamate transporters GLAST and GLT-1 represent critical astrocytic components enabling glutamate uptake for metabolism and recycling\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Tumor Microenvironment Remodeling and Immunomodulation\",\n      \"description\": \"Pathological remodeling of tissue microenvironment surrounding astrocytoma cells through inflammatory signaling, complement activation, extracellular matrix breakdown, and recruitment of immunosuppressive cell populations. This program transforms the normal brain microenvironment into a tumor-supportive niche that promotes proliferation and invasion while suppressing anti-tumor immunity.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Inflammatory cytokine signaling\",\n          \"genes\": [\"TNF\"],\n          \"citations\": [\n            {\n              \"source_id\": \"48\",\n              \"notes\": \"TNF encodes multifunctional proinflammatory cytokine mainly secreted by immune cells\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Complement system activation\",\n          \"genes\": [],\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Tumor mesenchymal stem-like cells secrete C5a, altering tumor microenvironment and promoting tumor progression through complement activation\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Extracellular matrix remodeling\",\n          \"genes\": [\"MMP16\", \"COL4A3\", \"COL4A4\", \"COL20A1\", \"VCAN\"],\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Extracellular matrix breakdown facilitates tumor cell invasion through tissue barriers\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Cell adhesion molecule dysregulation in tumor stroma\",\n          \"genes\": [\"CNTN1\", \"CNTN3\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Cell adhesion molecules mediate ECM interactions and are dysregulated in disease states\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Extracellular matrix proteoglycan organization\",\n          \"genes\": [\"VCAN\", \"CSPG5\"],\n          \"citations\": [\n            {\n              \"source_id\": \"41\",\n              \"notes\": \"Proteoglycans including versican contribute to extracellular matrix organization and tumor microenvironment structure\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Enhanced tumor cell invasion through matrix degradation\",\n        \"Immunosuppressive microenvironment limiting anti-tumor immunity\",\n        \"Recruitment of pro-tumor immune cell populations\",\n        \"Altered blood-brain barrier function enabling vascular permeability\"\n      ],\n      \"evidence_summary\": \"The tumor microenvironment represents a critical determinant of tumor behavior and therapeutic response, with malignant tumors actively remodeling their surrounding tissue to create a supportive niche. Complement system activation through C5a secretion recruits immunosuppressive myeloid populations that promote tumor growth and therapy resistance. Matrix metalloprotease expression enables invasion through basement membranes and white matter tracts, facilitating tumor infiltration. The inflammatory cytokine milieu simultaneously promotes tumor cell proliferation while suppressing adaptive immune responses through recruitment of regulatory T cells and myeloid-derived suppressor cells. In astrocytoma specifically, the microenvironment remodeling program contributes to seizure susceptibility through altered neuronal microenvironment and to therapy resistance through recruitment of immunosuppressive populations.\",\n      \"significance_score\": 0.81,\n      \"citations\": [\n        {\n          \"source_id\": \"41\",\n          \"notes\": \"Comprehensive study of complement-mediated microenvironment remodeling in glioblastoma\"\n        },\n        {\n          \"source_id\": \"48\",\n          \"notes\": \"TNF role in inflammatory microenvironment establishment\"\n        }\n      ],\n      \"supporting_genes\": [\"TNF\", \"MMP16\", \"COL4A3\", \"COL4A4\", \"COL20A1\", \"VCAN\", \"CSPG5\", \"CNTN1\", \"CNTN3\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"IL-6\", \"IL-8\", \"CCL2\"],\n        \"citations\": [\n          {\n            \"source_id\": \"41\",\n            \"notes\": \"Multiple inflammatory cytokines and chemokines constitute complete microenvironment remodeling program beyond those in input list\"\n          }\n        ]\n      }\n    },\n    {\n      \"program_name\": \"Synaptic Plasticity and Calcium-Dependent Signaling\",\n      \"description\": \"Molecular mechanisms underlying activity-dependent modification of synaptic strength and connectivity through calcium-dependent signaling cascades. This program encompasses calcium sensor proteins, calcium-responsive kinases, synaptic vesicle proteins, and presynaptic active zone organization enabling translation of calcium signals into changes in neurotransmitter release probability.\",\n      \"atomic_biological_processes\": [\n        {\n          \"name\": \"Calcium-dependent synaptic transmission\",\n          \"genes\": [\"RIMS1\", \"RIMS2\", \"CASK\", \"SYT16\"],\n          \"citations\": [\n            {\n              \"source_id\": \"34\",\n              \"notes\": \"CASK calcium/calmodulin-dependent serine protein kinase regulates synaptic function\"\n            },\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Synaptic vesicle cycle and signal release pathways involved in synaptic plasticity and homeostasis\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Synaptic vesicle organization and release\",\n          \"genes\": [\"SYN3\", \"STXBP5L\", \"RIMS1\", \"RIMS2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"RIMS proteins couple calcium to neurotransmitter release through organization of active zone complexes\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Activity-dependent gene expression downstream of calcium\",\n          \"genes\": [\"NCALD\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Calcium-dependent signaling regulates modification of post-synaptic structure and dendrite development\"\n            }\n          ]\n        }\n      ],\n      \"atomic_cellular_components\": [\n        {\n          \"name\": \"Presynaptic active zone organization\",\n          \"genes\": [\"RIMS1\", \"RIMS2\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Active zone proteins organize synaptic vesicles and coordinate calcium channels with exocytotic machinery\"\n            }\n          ]\n        },\n        {\n          \"name\": \"Synaptic vesicle cycle machinery\",\n          \"genes\": [\"SYN3\", \"STXBP5L\"],\n          \"citations\": [\n            {\n              \"source_id\": \"3\",\n              \"notes\": \"Synaptic vesicle recycling and availability control through synapsin and STXBP family proteins\"\n            }\n          ]\n        }\n      ],\n      \"predicted_cellular_impact\": [\n        \"Dysregulated synaptic strength modification through altered calcium sensitivity\",\n        \"Impaired synaptic plasticity and learning capacity\",\n        \"Altered neurotransmitter release characteristics and probability\",\n        \"Dysfunction of activity-dependent developmental refinement processes\"\n      ],\n      \"evidence_summary\": \"Synaptic plasticity represents the molecular basis of learning and memory, arising from activity-dependent modification of synaptic strength through calcium-dependent signaling cascades. Calcium influx through voltage-gated channels during neuronal activity triggers multiple signaling pathways controlling both presynaptic release probability and postsynaptic receptor density. RIMS family proteins specifically couple presynaptic calcium influx to neurotransmitter release through organization of active zone architecture bringing synaptic vesicles into proximity with voltage-gated calcium channels. Dysregulation of this calcium signaling program contributes to multiple neurological disorders and likely contributes to astrocytoma-associated seizures through aberrant network plasticity.\",\n      \"significance_score\": 0.79,\n      \"citations\": [\n        {\n          \"source_id\": \"34\",\n          \"notes\": \"CASK-mediated calcium-dependent signaling in synaptic organization\"\n        },\n        {\n          \"source_id\": \"3\",\n          \"notes\": \"Comprehensive pathway analysis of synaptic plasticity gene dysregulation\"\n        }\n      ],\n      \"supporting_genes\": [\"RIMS1\", \"RIMS2\", \"CASK\", \"SYT16\", \"SYN3\", \"STXBP5L\", \"NCALD\"],\n      \"required_genes_not_in_input\": {\n        \"genes\": [\"CAMK2A\", \"CAMK2B\", \"CALMODULIN\"],\n        \"citations\": [\n          {\n            \"source_id\": \"3\",\n            \"notes\": \"CAMK2B dysregulation in tauopathy; calmodulin-dependent kinases critical for calcium-dependent synaptic plasticity\"\n          }\n        ]\n      }\n    }\n  ],\n  \"method\": {\n    \"clustering_basis\": [\n      \"Pathway database integration (KEGG, Reactome, Gene Ontology)\",\n      \"Concurrent appearance in disease-relevant literature\",\n      \"Protein-protein interaction networks\",\n      \"Co-expression patterns in brain development and astrocytoma\",\n      \"Shared biological process participation\"\n    ],\n    \"notes\": \"Gene programs derived through systematic analysis of input gene list against published literature on astrocytoma biology, neural development, and astrocyte physiology. Programs identified represent coordinated functional modules where multiple input genes participate in the same biological process or cellular compartment. Programs ranked by significance score reflecting number of supporting genes, citation evidence density, and context-relevance to astrocytoma disease mechanisms. Programs emphasize both normal physiological roles and pathological dysregulation characteristic of astrocytoma.\"\n  },\n  \"version\": \"1.0\"\n}\n```",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/gene/6667",
      "https://www.ncbi.nlm.nih.gov/gene/4684",
      "https://www.nature.com/articles/s42003-025-08959-z",
      "https://www.ncbi.nlm.nih.gov/gene/546",
      "https://www.ncbi.nlm.nih.gov/gene/10752",
      "https://www.nature.com/articles/s41467-025-67166-w_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/44484",
      "https://www.ncbi.nlm.nih.gov/gene/2915",
      "https://www.ncbi.nlm.nih.gov/gene/2891",
      "https://www.ncbi.nlm.nih.gov/gene/108071",
      "https://www.nature.com/articles/s41380-025-03421-2",
      "https://www.ncbi.nlm.nih.gov/gene/27185",
      "https://www.nature.com/articles/s42003-025-08988-8",
      "https://www.nature.com/research-intelligence/nri-topic-summaries/nalcn-ion-channels-and-their-role-in-neuronal-function-micro-672855",
      "https://www.ncbi.nlm.nih.gov/gene/80031",
      "https://www.ncbi.nlm.nih.gov/gene/259232",
      "https://www.nature.com/articles/s41588-025-02419-4",
      "https://www.ncbi.nlm.nih.gov/gene/8850",
      "https://pubmed.ncbi.nlm.nih.gov/41331688/",
      "https://www.ncbi.nlm.nih.gov/gene/5156",
      "https://pubmed.ncbi.nlm.nih.gov/41395596/?fc=None&ff=20251215183737&v=2.18.0.post22+67771e2",
      "https://www.ncbi.nlm.nih.gov/gene/18747",
      "https://www.nature.com/articles/s41467-025-66120-0",
      "https://www.ncbi.nlm.nih.gov/gene/2895",
      "https://www.ncbi.nlm.nih.gov/gene/3725",
      "https://www.ncbi.nlm.nih.gov/gene/5521",
      "https://www.ncbi.nlm.nih.gov/gene/14804",
      "https://www.nature.com/articles/s41698-025-01190-3",
      "https://www.nature.com/articles/s41467-025-66109-9_reference.pdf",
      "https://www.ncbi.nlm.nih.gov/gene/57670",
      "https://www.ncbi.nlm.nih.gov/gene/20674",
      "https://www.ncbi.nlm.nih.gov/gene/8573",
      "https://connect.biorxiv.org/archive/",
      "https://www.ncbi.nlm.nih.gov/gene/4916",
      "https://www.ncbi.nlm.nih.gov/gene/4340",
      "https://www.ncbi.nlm.nih.gov/gene/18213",
      "https://www.ncbi.nlm.nih.gov/gene/361",
      "https://www.nature.com/articles/s41598-025-24116-2",
      "https://www.nature.com/articles/s41598-025-30853-1",
      "https://www.ncbi.nlm.nih.gov/gene/23239",
      "https://www.ncbi.nlm.nih.gov/gene/14415",
      "https://www.ncbi.nlm.nih.gov/gene/6935",
      "https://www.ncbi.nlm.nih.gov/gene/207",
      "https://www.ncbi.nlm.nih.gov/gene/5980",
      "https://www.ncbi.nlm.nih.gov/gene/6323",
      "https://www.ncbi.nlm.nih.gov/gene/7124",
      "https://www.ncbi.nlm.nih.gov/gene/10721",
      "https://www.ncbi.nlm.nih.gov/gene/6328",
      "http://json-schema.org/draft-07/schema#\","
    ],
    "duration_seconds": 269.6131248474121
  }
}